PillBot™: Micro-robotics now inside the Human Body
HAYWARD, Calif., July 2, 2024 /PRNewswire/ -- Endiatx, a pioneering Silicon Valley medical technology company, is shaping the future of...
Cancer
Digital Pathology Scanner Market Size to Grow USD 1,137 Million by 2030 at a CAGR of 10.31% | Valuates Reports
BANGALORE, India, July 2, 2024 /PRNewswire/ -- Digital Pathology Scanner Market is Segmented by Type (Fluorescence, Brightfield), by Application (Scientific Research,...
Body Vision Medical Announces Departure of David Webster as CEO and Appoints Matt Baker as Successor
CAMPBELL, Calif., July 2, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven intraoperative image guidance, announced today that...
Health In Tech, Adena Health, and OSU Health Plan Solutions Partner to Bring Affordable Level-Funded Health Plans to Ohio Employers
STUART, Fla., July 2, 2024 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and reimagines...
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival...
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Vaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines...
Mainz Biomed Provides Half Year 2024 Corporate Update
Industry Leading Clinical Data Position the Company for FDA Premarket Approval StudyBERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE...
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that...
Poolbeg Pharma PLC Announces Change of Registered Address
Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical...
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...
HistoIndex Charts New Course in Liver Disease Innovation: Announces Pivotal Changes to Scientific Advisory Board
Company to appoint Prof. Arun J. Sanyal as the new Chairman of HistoIndex's Scientific Advisory Board, bringing unparalleled expertise to...
Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leading Pharmacy and Retail Chains
CHICAGO, IL / ACCESSWIRE / July 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the...
CBIH Submits Groundbreaking Cannabis Patents for Breast and Pancreatic Cancer Treatments
Houston, Texas--(Newsfile Corp. - July 1, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce the...
Gilead Benefit Helps Employees Navigate Cancer Care
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before...
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute;...
Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors
Adding Decades of Public Company and Board Expertise as Prenetics Readies for Expansion into Consumer Health and WellnessLOS ANGELES, July...
Inside information: Orion upgrades full-year outlook for 2024
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST Inside information: Orion upgrades full-year outlook for...